retatrutide mechanism of action triple agonist glp-1 gip glucagon Main physiological actions the dual and Major physiological roles of GLP-1

GLP-1 medicines and the treatment of obesity GLP-1RAs led to weight loss investigations, with liraglutide 3 mg daily approved for weight loss in 2014, followed by semaglutide 2.4 mg weekly in 2021, and tirzepatide in 2023

Drug-drug interactions and the presence of other medications further increase the bleeding risk [143]

In recent years, diabetes treatment has focused more on increasing hormones

Nature Rev Endocrinol

Adipose-tissue specific deletion of dipeptidyl peptidase 4 (DPP4) enhances M2 macrophage markers and results in smaller adipocytes under HFD

This benefits several patients suffering from type 2 diabetes mellitus and obesity